메뉴 건너뛰기




Volumn 76, Issue 20, 2016, Pages 5983-5993

Evidence implicating immunological host effects in the efficacy of metronomic low-dose chemotherapy

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CYCLOPHOSPHAMIDE; ANTINEOPLASTIC ANTIMETABOLITE;

EID: 84991594138     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-16-0136     Document Type: Article
Times cited : (45)

References (42)
  • 1
    • 2942615257 scopus 로고    scopus 로고
    • Antiangiogenic basis of low-dose metronomic chemotherapy
    • Kerbel RS, Kamen BA. Antiangiogenic basis of low-dose metronomic chemotherapy. Nat Rev Cancer 2004;4:423-36.
    • (2004) Nat Rev Cancer , vol.4 , pp. 423-436
    • Kerbel, R.S.1    Kamen, B.A.2
  • 2
    • 21744437791 scopus 로고    scopus 로고
    • Repopulation of cancer cells during therapy: An important cause of treatment failure
    • Kim JJ, Tannock IF. Repopulation of cancer cells during therapy: an important cause of treatment failure. Nat Rev Cancer 2005;5:516-25.
    • (2005) Nat Rev Cancer , vol.5 , pp. 516-525
    • Kim, J.J.1    Tannock, I.F.2
  • 3
    • 50349097617 scopus 로고    scopus 로고
    • Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: Implications for antiangiogenic drugs as chemosensitizing agents
    • Shaked Y, Henke E, Roodhart JM, Mancuso P, Langenberg MH, Colleoni M, et al. Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell 2008;14:263-73.
    • (2008) Cancer Cell , vol.14 , pp. 263-273
    • Shaked, Y.1    Henke, E.2    Roodhart, J.M.3    Mancuso, P.4    Langenberg, M.H.5    Colleoni, M.6
  • 4
    • 34547617338 scopus 로고    scopus 로고
    • Antiangiogenic strategies on defense: On the possibility of blocking rebounds by the tumor vasculature after chemotherapy
    • Shaked Y, Kerbel RS. Antiangiogenic strategies on defense: on the possibility of blocking rebounds by the tumor vasculature after chemotherapy. Cancer Res 2007;67:7055-8.
    • (2007) Cancer Res , vol.67 , pp. 7055-7058
    • Shaked, Y.1    Kerbel, R.S.2
  • 5
    • 33749005405 scopus 로고    scopus 로고
    • Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors
    • Shaked Y, Ciarrocchi A, Franco M, Lee CR, Man S, Cheung AM, et al. Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science 2006;313:1785-7.
    • (2006) Science , vol.313 , pp. 1785-1787
    • Shaked, Y.1    Ciarrocchi, A.2    Franco, M.3    Lee, C.R.4    Man, S.5    Cheung, A.M.6
  • 6
    • 79955517032 scopus 로고    scopus 로고
    • TIE2-expressing macrophages limit the therapeutic efficacy of the vascular-disrupting agent combretastatin A4 phosphate in mice
    • Welford AF, Biziato D, Coffelt SB, Nucera S, Fisher M, Pucci F, et al. TIE2-expressing macrophages limit the therapeutic efficacy of the vascular-disrupting agent combretastatin A4 phosphate in mice. J Clin Invest 2011;121:1969-73.
    • (2011) J Clin Invest , vol.121 , pp. 1969-1973
    • Welford, A.F.1    Biziato, D.2    Coffelt, S.B.3    Nucera, S.4    Fisher, M.5    Pucci, F.6
  • 9
    • 81155132194 scopus 로고    scopus 로고
    • Host response to short-term, single-agent chemotherapy induces matrix metalloproteinase-9 expression and accelerates metastasis in mice
    • Gingis-Velitski S, Loven D, Benayoun L, Munster M, Bril R, Voloshin T, et al. Host response to short-term, single-agent chemotherapy induces matrix metalloproteinase-9 expression and accelerates metastasis in mice. Cancer Res 2011;71:6986-96.
    • (2011) Cancer Res , vol.71 , pp. 6986-6996
    • Gingis-Velitski, S.1    Loven, D.2    Benayoun, L.3    Munster, M.4    Bril, R.5    Voloshin, T.6
  • 10
    • 0034087691 scopus 로고    scopus 로고
    • Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity
    • Klement G, Baruchel S, Rak J, Man S, Clark K, Hicklin D, et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 2000;105:R15-24.
    • (2000) J Clin Invest , vol.105 , pp. R15-R24
    • Klement, G.1    Baruchel, S.2    Rak, J.3    Man, S.4    Clark, K.5    Hicklin, D.6
  • 11
    • 0034032882 scopus 로고    scopus 로고
    • Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer
    • Browder T, Butterfield CE, Kraling BM, Marshall B, O'Reilly MS, Folkman J. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000;60:1878-86.
    • (2000) Cancer Res , vol.60 , pp. 1878-1886
    • Browder, T.1    Butterfield, C.E.2    Kraling, B.M.3    Marshall, B.4    O'Reilly, M.S.5    Folkman, J.6
  • 12
    • 0034048358 scopus 로고    scopus 로고
    • Less is more, regularly: Metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice
    • Hanahan D, Bergers G, Bergsland E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 2000;105:1045-7.
    • (2000) J Clin Invest , vol.105 , pp. 1045-1047
    • Hanahan, D.1    Bergers, G.2    Bergsland, E.3
  • 13
    • 27644436870 scopus 로고    scopus 로고
    • The optimal biological dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity
    • Shaked Y, Emmengger U, Man S, Cervi D, Bertolini F, Ben-David Y, et al. The optimal biological dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity. Blood 2005;106:3058-61.
    • (2005) Blood , vol.106 , pp. 3058-3061
    • Shaked, Y.1    Emmengger, U.2    Man, S.3    Cervi, D.4    Bertolini, F.5    Ben-David, Y.6
  • 14
    • 84860815596 scopus 로고    scopus 로고
    • Metronomic cyclophosphamide treatment in metastasized breast cancer patients: Immunological effects and clinical outcome
    • Ge Y, Domschke C, Stoiber N, Schott S, Heil J, Rom J, et al. Metronomic cyclophosphamide treatment in metastasized breast cancer patients: immunological effects and clinical outcome. Cancer Immunol Immunother 2012;61:353-62.
    • (2012) Cancer Immunol Immunother , vol.61 , pp. 353-362
    • Ge, Y.1    Domschke, C.2    Stoiber, N.3    Schott, S.4    Heil, J.5    Rom, J.6
  • 15
    • 84876678701 scopus 로고    scopus 로고
    • Low-dose gemcitabine depletes regulatory T cells and improves survival in the orthotopic Panc02 model of pancreatic cancer
    • Shevchenko I, Karakhanova S, Soltek S, Link J, Bayry J, Werner J, et al. Low-dose gemcitabine depletes regulatory T cells and improves survival in the orthotopic Panc02 model of pancreatic cancer. Int J Cancer 2013;133: 98-107.
    • (2013) Int J Cancer , vol.133 , pp. 98-107
    • Shevchenko, I.1    Karakhanova, S.2    Soltek, S.3    Link, J.4    Bayry, J.5    Werner, J.6
  • 16
    • 33847368549 scopus 로고    scopus 로고
    • Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients
    • Ghiringhelli F, Menard C, Puig PE, Ladoire S, Roux S, Martin F, et al. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 2007;56:641-8.
    • (2007) Cancer Immunol Immunother , vol.56 , pp. 641-648
    • Ghiringhelli, F.1    Menard, C.2    Puig, P.E.3    Ladoire, S.4    Roux, S.5    Martin, F.6
  • 17
    • 84857723974 scopus 로고    scopus 로고
    • VEGF receptor inhibitors block the ability of metronomically dosed cyclophosphamide to activate innate immunity-induced tumor regression
    • Doloff JC, Waxman DJ. VEGF receptor inhibitors block the ability of metronomically dosed cyclophosphamide to activate innate immunity-induced tumor regression. Cancer Res 2012;72:1103-15.
    • (2012) Cancer Res , vol.72 , pp. 1103-1115
    • Doloff, J.C.1    Waxman, D.J.2
  • 18
    • 84900395848 scopus 로고    scopus 로고
    • Intermittent metronomic drug schedule is essential for activating antitumor innate immunity and tumor xenograft regression
    • Chen CS, Doloff JC, Waxman DJ. Intermittent metronomic drug schedule is essential for activating antitumor innate immunity and tumor xenograft regression. Neoplasia 2014;16:84-96.
    • (2014) Neoplasia , vol.16 , pp. 84-96
    • Chen, C.S.1    Doloff, J.C.2    Waxman, D.J.3
  • 19
    • 34248550985 scopus 로고    scopus 로고
    • Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors
    • Folkins C, Man S, Xu P, Shaked Y, Hicklin DJ, Kerbel RS. Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors. Cancer Res 2007;67:3560-4.
    • (2007) Cancer Res , vol.67 , pp. 3560-3564
    • Folkins, C.1    Man, S.2    Xu, P.3    Shaked, Y.4    Hicklin, D.J.5    Kerbel, R.S.6
  • 20
    • 77950815444 scopus 로고    scopus 로고
    • Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer
    • Hashimoto K, Man S, Xu P, Cruz-Munoz W, Tang T, Kumar R, et al. Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer. Mol Cancer Ther 2010;9:996-1006.
    • (2010) Mol Cancer Ther , vol.9 , pp. 996-1006
    • Hashimoto, K.1    Man, S.2    Xu, P.3    Cruz-Munoz, W.4    Tang, T.5    Kumar, R.6
  • 21
    • 84927618369 scopus 로고    scopus 로고
    • Postsurgical adjuvant or metastatic renal cell carcinoma therapy models reveal potent antitumor activity of metronomic oral topotecan with pazopanib
    • Jedeszko C, Paez-Ribes M, Di Desidero T, Man S, Lee CR, Xu P, et al. Postsurgical adjuvant or metastatic renal cell carcinoma therapy models reveal potent antitumor activity of metronomic oral topotecan with pazopanib. Sci Transl Med 2015;7:282ra50.
    • (2015) Sci Transl Med , vol.7
    • Jedeszko, C.1    Paez-Ribes, M.2    Di Desidero, T.3    Man, S.4    Lee, C.R.5    Xu, P.6
  • 22
    • 84907394550 scopus 로고    scopus 로고
    • Anti-Bv8 antibody and metronomic gemcitabine improve pancreatic adenocarcinoma treatment outcome following weekly gemcitabine therapy
    • Hasnis E, Alishekevitz D, Gingis-Veltski S, Bril R, Fremder E, Voloshin T, et al. Anti-Bv8 antibody and metronomic gemcitabine improve pancreatic adenocarcinoma treatment outcome following weekly gemcitabine therapy. Neoplasia 2014;16:501-10.
    • (2014) Neoplasia , vol.16 , pp. 501-510
    • Hasnis, E.1    Alishekevitz, D.2    Gingis-Veltski, S.3    Bril, R.4    Fremder, E.5    Voloshin, T.6
  • 23
    • 84929514070 scopus 로고    scopus 로고
    • Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): A phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group
    • Simkens LH, van Tinteren H, May A, ten Tije AJ, Creemers GJ, Loosveld OJ, et al. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group. Lancet 2015;385:1843-52.
    • (2015) Lancet , vol.385 , pp. 1843-1852
    • Simkens, L.H.1    Van Tinteren, H.2    May, A.3    Ten Tije, A.J.4    Creemers, G.J.5    Loosveld, O.J.6
  • 24
    • 84873086527 scopus 로고    scopus 로고
    • Low-dose metronomic chemotherapy: From past experience to new paradigms in the treatment of cancer
    • Loven D, Hasnis E, Bertolini F, Shaked Y. Low-dose metronomic chemotherapy: from past experience to new paradigms in the treatment of cancer. Drug Discov Today 2013;18:193-201.
    • (2013) Drug Discov Today , vol.18 , pp. 193-201
    • Loven, D.1    Hasnis, E.2    Bertolini, F.3    Shaked, Y.4
  • 25
    • 54449099774 scopus 로고    scopus 로고
    • Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer
    • Dellapasqua S, Bertolini F, Bagnardi V, Campagnoli E, Scarano E, Torrisi R, et al. Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. J Clin Oncol 2008;26:4899-905.
    • (2008) J Clin Oncol , vol.26 , pp. 4899-4905
    • Dellapasqua, S.1    Bertolini, F.2    Bagnardi, V.3    Campagnoli, E.4    Scarano, E.5    Torrisi, R.6
  • 26
    • 33645744835 scopus 로고    scopus 로고
    • Highly efficacious non-toxic treatment for advanced metastatic breast cancer using combination UFT-cyclophosphamide metronomic chemotherapy
    • Munoz R, Man S, Shaked Y, Lee C, Wong J, Francia G, et al. Highly efficacious non-toxic treatment for advanced metastatic breast cancer using combination UFT-cyclophosphamide metronomic chemotherapy. Cancer Res 2006;66:3386-91.
    • (2006) Cancer Res , vol.66 , pp. 3386-3391
    • Munoz, R.1    Man, S.2    Shaked, Y.3    Lee, C.4    Wong, J.5    Francia, G.6
  • 28
    • 81255135837 scopus 로고    scopus 로고
    • Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes
    • DeRose YS, Wang G, Lin YC, Bernard PS, Buys SS, Ebbert MT, et al. Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nat Med 2011;17:1514-20.
    • (2011) Nat Med , vol.17 , pp. 1514-1520
    • DeRose, Y.S.1    Wang, G.2    Lin, Y.C.3    Bernard, P.S.4    Buys, S.S.5    Ebbert, M.T.6
  • 29
    • 84938657323 scopus 로고    scopus 로고
    • Potential pro-invasive or metastatic effects of preclinical antiangiogenic therapy are prevented by concurrent chemotherapy
    • Paez-Ribes M, Man S, Xu P, Kerbel RS. Potential pro-invasive or metastatic effects of preclinical antiangiogenic therapy are prevented by concurrent chemotherapy. Clin Cancer Res 2015;21:5488-98.
    • (2015) Clin Cancer Res , vol.21 , pp. 5488-5498
    • Paez-Ribes, M.1    Man, S.2    Xu, P.3    Kerbel, R.S.4
  • 31
    • 84872084645 scopus 로고    scopus 로고
    • Metronomic oral topotecan prolongs survival and reduces liver metastasis in improved preclinical orthotopic and adjuvant therapy colon cancer models
    • Hackl C, Man S, Francia G, Milsom C, Xu P, Kerbel RS. Metronomic oral topotecan prolongs survival and reduces liver metastasis in improved preclinical orthotopic and adjuvant therapy colon cancer models. Gut 2013;62:259-71.
    • (2013) Gut , vol.62 , pp. 259-271
    • Hackl, C.1    Man, S.2    Francia, G.3    Milsom, C.4    Xu, P.5    Kerbel, R.S.6
  • 32
    • 0037093209 scopus 로고    scopus 로고
    • Antitumor and anti-angiogenic effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water
    • Man S, Bocci G, Francia G, Green S, Jothy S, Bergers G, et al. Antitumor and anti-angiogenic effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. Cancer Res 2002;62:2731-5.
    • (2002) Cancer Res , vol.62 , pp. 2731-2735
    • Man, S.1    Bocci, G.2    Francia, G.3    Green, S.4    Jothy, S.5    Bergers, G.6
  • 33
    • 84942082818 scopus 로고    scopus 로고
    • Blocking IL-1beta pathway following paclitaxel chemotherapy slightly inhibits primary tumor growth but promotes spontaneous metastasis
    • Voloshin T, Alishekevitz D, Kaneti L, Miller V, Isakov E, Kaplanov I, et al. Blocking IL-1beta pathway following paclitaxel chemotherapy slightly inhibits primary tumor growth but promotes spontaneous metastasis. Mol Cancer Ther 2015;14:1385-94.
    • (2015) Mol Cancer Ther , vol.14 , pp. 1385-1394
    • Voloshin, T.1    Alishekevitz, D.2    Kaneti, L.3    Miller, V.4    Isakov, E.5    Kaplanov, I.6
  • 35
    • 79955750055 scopus 로고    scopus 로고
    • Single-cell mass cytometry of differential immune and drug responses across a human hematopoietic continuum
    • Bendall SC, Simonds EF, Qiu P, Amir el AD, Krutzik PO, Finck R, et al. Single-cell mass cytometry of differential immune and drug responses across a human hematopoietic continuum. Science 2011;332:687-96.
    • (2011) Science , vol.332 , pp. 687-696
    • Bendall, S.C.1    Simonds, E.F.2    Qiu, P.3    Amir El, A.D.4    Krutzik, P.O.5    Finck, R.6
  • 37
    • 84879601793 scopus 로고    scopus 로고
    • The host immunological response to cancer therapy: An emerging concept in tumor biology
    • Voloshin T, Voest EE, Shaked Y. The host immunological response to cancer therapy: an emerging concept in tumor biology. Exp Cell Res 2013;319:1687-95.
    • (2013) Exp Cell Res , vol.319 , pp. 1687-1695
    • Voloshin, T.1    Voest, E.E.2    Shaked, Y.3
  • 38
    • 84939986130 scopus 로고    scopus 로고
    • Host effects contributing to cancer therapy resistance
    • Katz OB, Shaked Y. Host effects contributing to cancer therapy resistance. Drug Resist Updat 2015;19:33-42.
    • (2015) Drug Resist Updat , vol.19 , pp. 33-42
    • Katz, O.B.1    Shaked, Y.2
  • 39
    • 84973866691 scopus 로고    scopus 로고
    • Balancing efficacy of and host immune responses to cancer therapy: The yin and yang effects
    • Apr 26. [Epub ahead of print]
    • Shaked Y. Balancing efficacy of and host immune responses to cancer therapy: the yin and yang effects. Nat Rev Clin Oncol. 2016 Apr 26. [Epub ahead of print].
    • (2016) Nat Rev Clin Oncol
    • Shaked, Y.1
  • 40
    • 0041589524 scopus 로고    scopus 로고
    • Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells
    • Bertolini F, Paul S, Mancuso P, Monestiroli S, Gobbi A, Shaked Y, et al. Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res 2003;63:4342-6.
    • (2003) Cancer Res , vol.63 , pp. 4342-4346
    • Bertolini, F.1    Paul, S.2    Mancuso, P.3    Monestiroli, S.4    Gobbi, A.5    Shaked, Y.6
  • 41
    • 1642414466 scopus 로고    scopus 로고
    • Selective anti-endothelial effects of protracted low-dose BAL-9504, a novel geranylgeranyl-transferase inhibitor
    • Bocci G, Danesi R, Del Tacca M, Kerbel RS. Selective anti-endothelial effects of protracted low-dose BAL-9504, a novel geranylgeranyl-transferase inhibitor. Eur J Pharmacol 2003;477:17-21.
    • (2003) Eur J Pharmacol , vol.477 , pp. 17-21
    • Bocci, G.1    Danesi, R.2    Del Tacca, M.3    Kerbel, R.S.4
  • 42
    • 84874116665 scopus 로고    scopus 로고
    • Metronomic chemotherapy with low-dose cyclophosphamide plus gemcitabine can induce anti-tumor T cell immunity in vivo
    • Tongu M, Harashima N, Monma H, Inao T, Yamada T, Kawauchi H, et al. Metronomic chemotherapy with low-dose cyclophosphamide plus gemcitabine can induce anti-tumor T cell immunity in vivo. Cancer Immunol Immunother 2013;62:383-91.
    • (2013) Cancer Immunol Immunother , vol.62 , pp. 383-391
    • Tongu, M.1    Harashima, N.2    Monma, H.3    Inao, T.4    Yamada, T.5    Kawauchi, H.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.